Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05739942 · ClinicalTrials.gov registry record · Phase 1
Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma
A Phase 1 study of Newly Diagnosed and Recurrent Glioblastoma, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 20
- Study locations
NCT05739942 is a Phase 1 study of Newly Diagnosed and Recurrent Glioblastoma that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 40 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT05739942, a Phase 1 study of Newly Diagnosed and Recurrent Glioblastoma, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will investigate different doses of \[177Lu\]Lu-NeoB in combination with RT and TMZ in participants with newly diagnosed glioblastoma, with methylated or unmethylated promoter, to assess the safety and efficacy of \[177Lu\]Lu-NeoB in combination with the SoC and in recurrent glioblastoma as single agent, to identify the recommended dose and to also explore the safety of the PET imaging agent \[68Ga\]Ga-NeoB and characterize its uptake in the tumor area.
Conditions Studied
Interventions
- DRUG [68Ga]Ga-NeoB
- DRUG [177Lu]Lu-NeoB
- OTHER Temozolomide
Study Locations (20)
Other
- Novartis Investigative Site - Marseille
- Novartis Investigative Site - Essen
- Novartis Investigative Site - München
- Novartis Investigative Site - Rostock
- Novartis Investigative Site - Jerusalem
- Novartis Investigative Site - Porto
- Novartis Investigative Site - Barcelona
Catalonia
- Novartis Investigative Site - Badalona
- Novartis Investigative Site - Barcelona
California
- University of California LA - Los Angeles
Colorado
- University of Colorado Denver - Aurora
Florida
- Mayo Clinic Jacksonville - Jacksonville
Massachusetts
- Dana Farber Cancer Institute - Boston
New York
- Memorial Sloan Kettering Cancer Ctr - New York
Ohio
- Univ Hosp Cleveland Medical Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-05-15 |
| Est. Completion | 2032-07-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05739942
The ClinicalTrials.gov registry entry for NCT05739942 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Newly Diagnosed and Recurrent Glioblastoma appearing as the primary indexed condition, and to 3 interventions - of which [68Ga]Ga-NeoB is the first listed.
NCT05739942 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, Catalonia, California.
Frequently Asked Questions
What is clinical trial NCT05739942 about?
NCT05739942 is a clinical study titled "Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma". This study will investigate different doses of \[177Lu\]Lu-NeoB in combination with RT and TMZ in participants with newly diagnosed glioblastoma, with methylated or unmethylated promoter, to assess the safety and efficacy of \[177Lu\]Lu-NeoB in combination with the SoC and in recurrent glioblastoma ...
What is the current status of trial NCT05739942?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2024-05-15. Estimated completion is 2032-07-01.
What conditions does trial NCT05739942 study?
This clinical trial studies the following conditions: Newly Diagnosed and Recurrent Glioblastoma.
What interventions are being tested in trial NCT05739942?
The interventions under investigation include: [68Ga]Ga-NeoB (DRUG), [177Lu]Lu-NeoB (DRUG), Temozolomide (OTHER).
Who is sponsoring clinical trial NCT05739942?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05739942 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.